



QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO :			REPORT NO : EFRAC/2023/DRG/RG/03403						
	alayan Medical Drugs Ar			ISSUE DATE : 31/10/2023					
			ah, Office of the mission	CUSTOMER REFERENCE : TRF					
	or,NHM, Shillong, East K	hasi Hi	lls Meghalaya, 793003	DATE : 28/09/2023 PAGE NO : 1 of 2					
MFG. 1	LACENCE NO :								
			SAN	IPLE DETAILS	2	OY			
<u>SAMP</u>	LE REGISTRATION D	ETAIL	<u>.S</u>		1.1	AV.			
Sample Name		: Tab Ibuprofen- 200mg		Sample Quantity Received : 80.00 Tablets					
				Sample Registration Date : 26/10/2023					
				wn by 💦 : Client					
				Batch Size : N/A					
Sample Receipt Date		: 28/	09/2023	Date of	Date of Expiry : Apr-2026				
Registration No		: EFRAC/2023/DRG/RG/03403							
Name of Manufacturer		: N/A							
Batch No.		: MMDSL/QC-0005							
			1.00		(P)				
Date of Mfg.		: May-2023							
<u>SAMP</u>	LE ANALYSIS DETAIL	<u>S</u>		125					
Analys	is Starting Date	: 30	/10/2023	Analysi	s Completion Da	te : 31/10/202	3		
		1		TEST RESULT					
SL No.	TEST PARAMETER	4	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS		
1	Dissolution	1	Indian Pharmacopoeia 2022	200	% of L.C.	NLT 80.0	Avg : 98.88 , Min :		
		2	Y SY	mg/Tab	04		97.45 , Max : 102.88		
2	Unifromity of Weight	1	Indian Pharmacopoeia 2022	-	%	(±)5.0	Ava wt : 283.73 ma .		

	A 2		mg/Tab			97.45 , Max : 102.88
2	Unifromity of Weight	Indian Pharmacopoeia 2022	-	%	(±)5.0	Avg wt : 283.73 mg ,
						(-) Dev : 1.80 , (+)
						Dev : 2.42
3	Assay	Indian Pharmacopoeia 2022	200	% of L.C.	95.0 - 105.0	99.17
			mg/Tab			
4	Identification	Indian Pharmacopoeia 2022	-	_	The IR spectrum of	The IR spectrum of
					the sample should	the sample found
					concordant with that	concordant with that
					the spectrum of IPRS	the spectrum of IPRS
					of ibuprofen.	of ibuprofen.
5	Disintegration test	Indian Pharmacopoeia 2022	-	Min./Sec.	NMT 30 Minutes	Min : 05 Min 20 Sec ,
	-					Max : 06 Min 40 Sec



Research & Analysis Centre: Subhas Nagar PO: Nilgunj Bazaar Barasat Kolkata 700 121 Phone +91 33 7112 2800 Fax: +91 337112 2801 Email: <u>efraclab@efrac.org</u> www.efrac.org







QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO :	REPORT NO :	EFRAC/2023/DRG/RG/03403
Meghalayan Medical Drugs And Services Limited	ISSUE DATE :	31/10/2023
New colony shillong, DHS, laitumkhrah, Office of the mission	CUSTOMER REFERENCE :	TRF
director,NHM, Shillong, East Khasi Hills Meghalaya, 793003	DATE :	28/09/2023
Shillongcencence :	PAGE NO :	2 of 2

In the opinion of the undersigned, the Sample referred to above <u>is of Standard Quality</u> / <u>is not of Standard Quality</u> as defined in the Act or the Rules madethere under for the reasons given below:

- Date : 31/10/2023
- UOM : Unit of Measurement
- REMARKS : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the result obtained for tested parameter only.
- Note : This Report is valid only for use in Indian (Domestic) Market & is Not valid for use in any International Market.

-END OF THE TEST REPORT-



